
[Federal Register: September 2, 2008 (Volume 73, Number 170)]
[Notices]               
[Page 51309]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr02se08-63]                         

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2008-N-0466]

 
Over the Counter Cough and Cold Medication for Pediatric Use; 
Notice of Public Hearing; Correction

AGENCY:  Food and Drug Administration, HHS.

ACTION: Notice of public hearing; request for comments; correction.

-----------------------------------------------------------------------

SUMMARY:  The Food and Drug Administration is correcting a notice that 
published in the Federal Register on August 25, 2008 (73 FR 50033). The 
notice announced a public hearing to obtain input regarding over-the-
counter (OTC) cough and cold drugs marketed for pediatric use. Due to 
some confusion regarding electronic registration, this notice revises 
the electronic registration procedures, and corrects the address for 
the contact person.

DATES: The correction is effective September 2, 2008.

FOR FURTHER INFORMATION CONTACT: Faith Dugan, Food and Drug 
Administration, 10903 New Hampshire Ave., rm. 6182, Silver Spring, MD 
20993, 301-796-3446, Faith.Dugan@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: In FR Doc. E8-19657, published on August 25, 
2008 (73 FR 50033), the following correction is made to ADDRESSES:
    1. On page 50033, in the first and second columns, the ADDRESSES 
section is corrected to read as follows:
ADDRESSES: Submit written comments to the Division of Dockets 
Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, 
rm. 1061, Rockville, MD 20852.
    E-mail electronic registration to: Faith.Dugan@fda.hhs.gov. Anyone 
who has already registered via http://www.regulations.gov does not have 
to re-register. The agency will accept those registrations.
    Submit electronic comments to http://www.regulations.gov. All 
comments should be identified with the docket number found in brackets 
in the heading of this document.
    Transcripts of the hearing will be available for review at the 
Division of Dockets Management and on the Internet at http://
www.regulations.gov approximately 30 days after the hearing.
    For Registration to Attend and/or Participate in the Hearing: 
Seating at the hearing is limited. People interested in attending 
should submit electronic registration to Faith Dugan by close of 
business on September 15, 2008. Registration is free and will be on a 
first-come, first-served basis. Written or electronic comments will be 
accepted until December 2, 2008.
    If you wish to make an oral presentation at the hearing, you must 
state your intention on your registration submission (see ADDRESSES). 
To speak, submit your name, title, business affiliation, address, 
telephone and fax numbers, and e-mail address. FDA has included 
questions for comment in section II of this document. You should also 
identify by number each question you wish to address in your 
presentation. FDA will do its best to accommodate requests to speak. 
Individuals and organizations with common interests are urged to 
consolidate or coordinate their presentations, and to request time for 
a joint presentation. FDA will determine the amount of time allotted to 
each presenter and the approximate time that each oral presentation is 
scheduled to begin.
    If you need special accommodations because of a disability, please 
inform Faith Dugan, (see For Information on the Hearing Contact).
    For Information on the Hearing Contact: Faith Dugan, Food and Drug 
Administration, 10903 New Hampshire Ave., rm. 6182, Silver Spring, MD 
20993 , 301-796-3446, FAX: 301-847-4752, e-mail: 
Faith.Dugan@fda.hhs.gov.

    Dated: August 27, 2008.
Jeffrey Shuren,
Associate Commissioner for Policy and Planning.
[FR Doc. E8-20370 Filed 8-28-08; 11:15 am]

BILLING CODE 4160-01-S
